Oryzon Genomics S.A. (ORYZF)
USD 1.79
(0.0%)
USD 1.79
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 25.12 Million EUR | -19.28% |
| 2022 | 31.12 Million EUR | 29.04% |
| 2021 | 24.12 Million EUR | 32.72% |
| 2020 | 18.17 Million EUR | -4.16% |
| 2019 | 18.96 Million EUR | -15.05% |
| 2018 | 22.32 Million EUR | -16.11% |
| 2017 | 26.61 Million EUR | -1.49% |
| 2016 | 27.01 Million EUR | 105.63% |
| 2015 | 13.13 Million EUR | 8.0% |
| 2014 | 12.16 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 26.89 Million USD | -7.78% |
| 2024 Q3 | 25.8 Million EUR | 6.82% |
| 2024 Q2 | 24.15 Million EUR | 4.26% |
| 2023 Q1 | 27.57 Million EUR | -11.42% |
| 2023 FY | 25.12 Million EUR | -19.28% |
| 2023 Q4 | 25.12 Million EUR | 9.17% |
| 2023 Q3 | 23.01 Million EUR | -11.82% |
| 2023 Q2 | 26.1 Million EUR | -5.35% |
| 2022 Q1 | 23.44 Million USD | -2.81% |
| 2022 Q4 | 31.12 Million EUR | -9.78% |
| 2022 Q2 | 26.21 Million EUR | 11.83% |
| 2022 FY | 31.12 Million EUR | 29.04% |
| 2022 Q3 | 34.5 Million USD | 31.59% |
| 2021 Q3 | -0.47 USD | -100.0% |
| 2021 Q4 | 24.12 Million USD | 5096821460.96% |
| 2021 Q1 | 21.3 Million EUR | 17.2% |
| 2021 Q2 | 20.34 Million EUR | -4.49% |
| 2021 FY | 24.12 Million EUR | 32.72% |
| 2020 Q1 | 17.12 Million EUR | -9.71% |
| 2020 Q4 | 18.17 Million EUR | -7.5% |
| 2020 Q3 | 19.64 Million EUR | -12.43% |
| 2020 FY | 18.17 Million EUR | -4.16% |
| 2020 Q2 | 22.43 Million EUR | 31.04% |
| 2019 Q1 | 21.28 Million EUR | -4.64% |
| 2019 FY | 18.96 Million EUR | -15.05% |
| 2019 Q4 | 18.96 Million EUR | 3.28% |
| 2019 Q3 | 18.36 Million EUR | -6.03% |
| 2019 Q2 | 19.54 Million EUR | -8.21% |
| 2018 Q1 | 25.73 Million EUR | -3.29% |
| 2018 FY | 22.32 Million EUR | -16.11% |
| 2018 Q4 | 22.32 Million EUR | 0.04% |
| 2018 Q3 | 22.31 Million EUR | -5.93% |
| 2018 Q2 | 23.72 Million EUR | -7.83% |
| 2017 Q4 | 26.61 Million EUR | 13.45% |
| 2017 Q1 | 30.85 Million EUR | 14.22% |
| 2017 FY | 26.61 Million EUR | -1.49% |
| 2017 Q2 | 25.37 Million EUR | -17.76% |
| 2017 Q3 | 23.45 Million EUR | -7.57% |
| 2016 FY | 27.01 Million EUR | 105.63% |
| 2016 Q1 | 21.86 Million EUR | 66.45% |
| 2016 Q2 | 26.2 Million EUR | 19.85% |
| 2016 Q4 | 27.01 Million EUR | 1.22% |
| 2016 Q3 | 26.69 Million EUR | 1.84% |
| 2015 FY | 13.13 Million EUR | 8.0% |
| 2015 Q4 | 13.13 Million EUR | 0.0% |
| 2014 FY | 12.16 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 52.865% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -162.215% |
| SQZ Biotechnologies Company | 50.03 Million USD | 49.788% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 65.33% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 57.425% |
| Mesoblast Limited | 188.44 Million USD | 86.667% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -552.369% |
| Genus plc | 485 Million USD | 94.819% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -330.038% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -898.498% |
| Marizyme, Inc. | 26.67 Million USD | 5.811% |
| ContraFect Corporation | 32.53 Million USD | 22.764% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -561.197% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1168.127% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -556.421% |
| Intellipharmaceutics International Inc. | 12 Million USD | -109.226% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -113.322% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1553090.453% |
| Accustem Sciences Inc. | 1.07 Million USD | -2228.075% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 67.545% |
| EV Biologics, Inc. | 2.11 Million USD | -1087.928% |
| Q BioMed Inc. | 8.13 Million USD | -208.935% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 69.705% |
| Neon Bloom, Inc. | 1.22 Million USD | -1949.032% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -388.25% |
| Biomind Labs Inc. | 1.49 Million USD | -1576.584% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 89.706% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -36.526% |
| Skye Bioscience, Inc. | 14.07 Million USD | -78.547% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1149.944% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -17582.182% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -165.431% |
| IMV Inc. | 37.93 Million USD | 33.763% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -12393.037% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -337.283% |
| GB Sciences, Inc. | 5.41 Million USD | -363.779% |
| Alpha Cognition Inc. | 7.16 Million USD | -250.681% |
| HST Global, Inc. | 593.59 Thousand USD | -4132.782% |
| CSL Limited | 18.62 Billion USD | 99.865% |
| Halberd Corporation | 728.71 Thousand USD | -3347.899% |
| Enzolytics Inc. | 365.26 Million USD | 93.121% |
| Resverlogix Corp. | 67.39 Million USD | 62.72% |
| Affymax, Inc. | 8.87 Million USD | -183.232% |
| SYBLEU INC | 681.41 Thousand USD | -3587.264% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2895.652% |
| argenx SE | 444.95 Million USD | 94.353% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 66.464% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1365.898% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -111.084% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -585.522% |
| AVAX Technologies, Inc. | 3.99 Million USD | -529.121% |
| Zenith Capital Corp. | 27.56 Thousand USD | -91036.77% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.105% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -10428.001% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -572.829% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -3590.4% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 78.837% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -177.869% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -37440.522% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1652.296% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 50.013% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -826.579% |
| BioStem Technologies, Inc. | 15.9 Million USD | -57.976% |
| ONE Bio Corp. | 27.49 Million USD | 8.621% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -5306.832% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -91488.583% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1895.365% |
| Agentix Corp. | 2.51 Million USD | -900.794% |
| LadRx Corporation | 2.2 Million USD | -1041.794% |
| Cell Source, Inc. | 15.8 Million USD | -58.955% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -56114.194% |
| Regen BioPharma, Inc. | 5.45 Million USD | -360.375% |
| Regen BioPharma, Inc. | 5.45 Million USD | -360.375% |
| NovAccess Global Inc. | 7.86 Million USD | -219.633% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -1.533% |
| Itoco Inc. | 1.65 Million USD | -1419.855% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1124.699% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -315.366% |
| Kadimastem Ltd | 3.5 Million USD | -616.874% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -5860.01% |
| CytoDyn Inc. | 127.89 Million USD | 80.354% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -60010.28% |
| Mobile Lads Corp. | 1.31 Million USD | -1812.87% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1504.052% |
| Qrons Inc. | 1.48 Million USD | -1587.733% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -127.477% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -3006.538% |
| Rebus Holdings, Inc. | 5.24 Million USD | -379.311% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -311.765% |
| International Stem Cell Corporation | 5.27 Million USD | -376.132% |
| Bioxytran, Inc. | 3.24 Million USD | -673.211% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -3914.882% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -444.181% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 38.712% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -12.848% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1140.528% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -358.662% |
| Neutra Corp. | 973.52 Thousand USD | -2480.868% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 13.405% |
| PureTech Health plc | 125.58 Million USD | 79.993% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -568.743% |
| IXICO plc | 1.9 Million USD | -1222.191% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -22.39% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 75.683% |
| CSL Limited | 18.62 Billion USD | 99.865% |
| Cellectis S.A. | 249.36 Million USD | 89.924% |